Vergoeding 2018-2022 voor ATC-subgroep G04BD : Middelen bij urge-incontinentie
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| G04BD02 Flavoxaat (Urispas ®) | 93.555 | 84.011 | 85.235 | 79.812 | 70.699 |
| G04BD04 Oxybutynine (Dridase ®) | 611.250 | 1.528.100 | 1.698.400 | 2.470.800 | 3.578.800 |
| G04BD07 Tolterodine (Detrusitol ®) | 534.660 | 682.920 | 705.780 | 646.780 | 671.310 |
| G04BD08 Solifenacine (Vesicare ®) | 12.467.500 | 11.771.200 | 6.749.000 | 4.280.200 | 4.008.000 |
| G04BD10 Darifenacine (Emselex ®) | 1.323.600 | 1.271.300 | 1.218.000 | 1.171.700 | 1.237.500 |
| G04BD11 Fesoterodine (Toviaz ®) | 1.273.800 | 1.274.500 | 1.245.500 | 1.217.800 | 1.151.700 |
| G04BD12 Mirabegron (Betmiga ®) | 5.114.300 | 5.701.200 | 6.077.200 | 6.558.300 | 7.340.800 |
| Totaal | 21.418.665 | 22.313.231 | 17.779.115 | 16.425.392 | 18.058.809 |